Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

Howes, O, Bose, S, Turkheimer, F, Valli, I, Egerton, A, Stahl, D, Valmaggia, L, Allen, P +2 more·2011·Molecular Psychiatry
DOI 10.1038/mp.2011.20

Cited by (292)

Items 101–200 of 292

  1. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes
    Gemma Modinos, Anja Richter, Alice Egerton, Ilaria Bonoldi, Matilda Azis, Mathilde Antoniades, Matthijs Geert Bossong, Nicolas Andres Crossley, Jesús Pérez, James M. Stone et al. · 2021 · Neuropsychopharmacology
  2. Models of persecutory delusions: a mechanistic insight into the early stages of psychosis
    Andreea Oliviana Diaconescu, Daniel J. Hauke, Stefan Borgwardt · 2019 · Molecular Psychiatry
  3. Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis
    Schmidt, A., Antoniades, M., Allen, P., Egerton, A., Chaddock, C. A., Borgwardt, S., Fusar-Poli, P., Roiser, J. P., Howes, O., McGuire, P. · 2017 · Psychological Medicine
  4. Dopamine D<sub>2</sub> and D<sub>3</sub> binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task
    Suridjan, Ivonne, Rusjan, Pablo, Addington, Jean, Wilson, Alan A., Houle, Sylvain, Mizrahi, Romina · 2013 · Journal of Psychiatry and Neuroscience
  5. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis
    Bloemen, Oswald J.N., de Koning, Mariken B., Gleich, Tobias, Meijer, Julia, de Haan, Lieuwe, Linszen, Don H., Booij, Jan, van Amelsvoort, Thérèse A.M.J. · 2013 · European Neuropsychopharmacology
  6. Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome
    Scott Richard Clark, Klaus Oliver Schubert, Bernhard Theodor Baune · 2014 · Journal of Neural Transmission
  7. Carriers of an apolipoprotein E epsilon 4 allele are more vulnerable to a dietary deficiency in omega-3 fatty acids and cognitive decline
    Tanya Gwendolyn Nock, Raphaël Chouinard‐Watkins, Mélanie Plourde · 2017 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  8. Early Detection and Intervention in Bipolar Affective Disorder: Targeting the Development of the Disorder
    Oliver David Howes, Irina Falkenberg · 2011 · Current Psychiatry Reports
  9. Glutamate and Psychosis Risk
    Egerton, Alice, Fusar-Poli, Paolo, M. Stone, James · 2012 · Current Pharmaceutical Design
  10. Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia
    Susan F. Sonnenschein, Anthony A. Grace · 2019 · Neuropharmacology
  11. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study
    Oliver David Howes, Ilaria Bonoldi, Robert Ali McCutcheon, Matilda Azis, Mathilde Antoniades, Matthijs Geert Bossong, Gemma Modinos, Jesús Pérez, James M. Stone, Barbara Santangelo et al. · 2019 · Neuropsychopharmacology
  12. Dopamine and glutamate in individuals at high risk for psychosis: a meta‐analysis of in vivo imaging findings and their variability compared to controls
    Robert Ali McCutcheon, Kate Merritt, Oliver David Howes · 2021 · World Psychiatry
  13. Third-generation neuroimaging in early schizophrenia: Translating research evidence into clinical utility
    Stefan Borgwardt, Paolo Fusar‐Poli · 2012 · The British Journal of Psychiatry
  14. Evidence That Environmental and Genetic Risks for Psychotic Disorder May Operate by Impacting on Connections Between Core Symptoms of Perceptual Alteration and Delusional Ideation
    Feikje Smeets, Tineke Lataster, Wolfgang Viechtbauer, Philippe Delespaul, G.R.O.U.P. · 2014 · Schizophrenia Bulletin
  15. Prevention of psychosis: moving on from the at-risk mental state to universal primary prevention
    Robin M. Murray, Anthony S. David, Olesya Ajnakina · 2020 · Psychological Medicine
  16. Circuit-Based Approaches to Understanding Corticostriatothalamic Dysfunction Across the Psychosis Continuum
    Kristina Sabaroedin, Jeggan Tiego, Alex Fornito · 2022 · Biological Psychiatry
  17. Cognitive control of gaze in bipolar disorder and schizophrenia
    Katharine N. Thakkar, Jeffrey D. Schall, Gordon D. Logan, Sohee Park · 2015 · Psychiatry Research
  18. Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective
    Alejandro De Los Angeles, Michael B. Fernando, Nicola Hall, Kristen Brennand, Paul J. Harrison, Brady J. Maher, Daniel R. Weinberger, Elizabeth M. Tunbridge · 2021 · Biological Psychiatry
  19. Cognitive control network connectivity differentially disrupted in treatment resistant schizophrenia
    Charlotte Mary Horne, Lucy D. Vanes, Tess Verneuil, Elias D. Mouchlianitis, Timea Szentgyorgyi, Bruno B. Averbeck, Robert Leech, Rosalyn Moran, Sukhwinder Singh Shergill · 2021 · NeuroImage Clinical
  20. Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study
    Maria Rogdaki, Céline Devroye, Mariasole Ciampoli, Mattia Veronese, Abhishekh Hulegar Ashok, Robert Ali McCutcheon, Sameer Jauhar, Ilaria Bonoldi, Maria Gudbrandsen, Eileen Daly et al. · 2021 · Molecular Psychiatry
  21. HERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through DRD2/PP2A/AKT1/GSK3 for Schizophrenia Risk
    Qiujin Yan, Xiulin Wu, Ping Zhou, Yan Zhou, Xuhang Li, Zhongchun Liu, Huawei Tan, Wei Yao, Yaru Xia, Fan Zhu · 2022 · Viruses
  22. Increased resting perfusion of the hippocampus in high positive schizotypy: A pseudocontinuous arterial spin labeling study
    Gemma Modinos, Alice Egerton, Katrina McMullen, Anna Patricia McLaughlin, Veena Kumari, Gareth J. Barker, Steven Williams, Fernando O. Zelaya · 2018 · Human Brain Mapping
  23. Application of positron emission tomography in psychiatry—methodological developments and future directions
    Cervenka, Simon, Frick, Andreas, Bodén, Robert, Lubberink, Mark · 2022 · Translational Psychiatry
  24. How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis?
    Matthew J. Kempton, Philip K. McGuire · 2014 · European Neuropsychopharmacology
  25. Regional brain volume changes following chronic antipsychotic administration are mediated by the dopamine D2 receptor
    Elisa Guma, J. Rocchetti, Gabriel A. Devenyi, A. Tanti, Axel Mathieu, J. Lerch, G. Elgbeili, B. Courcot, N. Mechawar, M. Chakravarty et al. · 2018 · NeuroImage
  26. Neuroimaging Findings in the At-Risk Mental State: A Review of Recent Literature
    Stephen James Wood, Renate L. E. P. Reniers, Kareen Heinze · 2013 · The Canadian Journal of Psychiatry
  27. Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review
    Kelly Rootes-Murdy, David R. Goldsmith, Jessica A. Turner · 2022 · Frontiers in Integrative Neuroscience
  28. Spatial working memory ability in individuals at ultra high risk for psychosis
    Vina M. Goghari, Caroline Brett, P. Tabraham, Louise Johns, Lucia Valmaggia, Matthew R. Broome, James Woolley, Elvira Bramon, Oliver David Howes, Majella Byrne et al. · 2014 · Journal of Psychiatric Research
  29. Antipsychotic Interventions in Prodromal Psychosis
    Chen‐Chung Liu, Arsime Demjaha · 2013 · CNS Drugs
  30. Motion energy analysis reveals altered body movement in youth at risk for psychosis
    Derek J. Dean, Alayna T. Samson, Raeana E. Newberry, Vijay Anand Mittal · 2017 · Schizophrenia Research
  31. Can circular inference relate the neuropathological and behavioral aspects of schizophrenia?
    Pantelis Leptourgos, Sophie Denève, Renaud Jardri · 2017 · Current Opinion in Neurobiology
  32. The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study
    Enrico D’Ambrosio, Sameer Jauhar, Seoyoung Kim, Mattia Veronese, Maria Rogdaki, Fiona Pepper, Ilaria Bonoldi, Vasileia Kotoula, Matthew J. Kempton, Federico Turkheimer et al. · 2019 · Molecular Psychiatry
  33. Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for Conversion
    Justin K. Ellis, Elaine F. Walker, David R. Goldsmith · 2020 · Frontiers in Psychiatry
  34. Altered Resting-State Brain Activity in Schizophrenia and Obsessive-Compulsive Disorder Compared With Non-psychiatric Controls: Commonalities and Distinctions Across Disorders
    Yuyanan Zhang, Jinmin Liao, Qianqian Li, Xiao Zhang, Lijun Liu, Jun Yan, Dai Zhang, Hao Yan, Weihua Yue · 2021 · Frontiers in Psychiatry
  35. Associating Multimodal Neuroimaging Abnormalities With the Transcriptome and Neurotransmitter Signatures in Schizophrenia
    Yuling Luo, Debo Dong, Huan Huang, Jingyu Zhou, Xiaojun Zuo, Jian Hao Hu, Hui He, Sisi Jiang, Mingjun Duan, Dezhong Yao et al. · 2023 · Schizophrenia Bulletin
  36. Australian guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis: report from the AACB Sweat Testing Working Party.
    John Coakley, Sue Scott, James C.G. Doery, Ronda Greaves, Peter Talsma, Elaine Whitham, Janet Winship · 2006 · PubMed
  37. Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence.
    M. Bauer, N. Praschak-rieder, S. Kasper, M. Willeit · 2012 · Current pharmaceutical design
  38. Generalizability and Out-of-Sample Predictive Ability of Associations Between Neuromelanin-Sensitive Magnetic Resonance Imaging and Psychosis in Antipsychotic-Free Individuals
    Kenneth Wengler, Seth C. Baker, Anastasia Velikovskaya, Alissa Fogelson, Ragy R. Girgis, Francisco Reyes-Madrigal, Seonjoo Lee, Camilo de la Fuente‐Sandoval, Najate Ojeil, Guillermo Horga · 2023 · JAMA Psychiatry
  39. From "bedside" to "bench" and back: A translational approach to studying dopamine dysfunction in schizophrenia.
    A. Abi-Dargham · 2020 · Neuroscience and Biobehavioral Reviews
  40. Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis
    Seoyoung Kim, Sang Ho Shin, Barbara Santangelo, Mattia Veronese, Seung Kwan Kang, Jae Sung Lee, Gi Jeong Cheon, Woojoo Lee, Jun Soo Kwon, Oliver David Howes et al. · 2020 · Molecular Psychiatry
  41. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis
    Susan F. Sonnenschein, Anthony A. Grace · 2020 · Expert Opinion on Therapeutic Targets
  42. Psychotic reactivity to daily life stress and the dopamine system: A study combining experience sampling and [¹⁸F]fallypride positron emission tomography.
    Dennis Hernaus, Dina Collip, Johan Lataster, Wolfgang Viechtbauer, Erik Myin, Jenny Ceccarini, Koen Van Laere, Jim van Os, Inez Myin‐Germeys · 2015 · Journal of Abnormal Psychology
  43. Psychotic symptoms in youth with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) may reflect syndrome severity and heterogeneity
    Melissa A. Silverman, Jennifer Frankovich, Emily Nguyen, Collin McCloskey Leibold, Jong H. Yoon, G. Mark Freeman, Hannah C. Karpel, Margo Thienemann · 2018 · Journal of Psychiatric Research
  44. Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia
    A. Petty, Xiao-Ying Cui, Y. Tesiram, D. Kirik, O. Howes, D. Eyles · 2019 · npj Schizophrenia
  45. Dopamine manipulations modulate paranoid social inferences in healthy people
    Joseph M Barnby, Vaughan Bell, Quinton Deeley, Mitul Ashok Mehta · 2020 · Translational Psychiatry
  46. Individual and combined effects of cannabidiol and Δ 9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain
    Matthew B. Wall, Tom P. Freeman, Chandni Hindocha, Lysia Demetriou, Natalie Ertl, Abigail M. Freeman, A. Jones, Will Lawn, Rebecca Anne Pope, Claire Mokrysz et al. · 2022 · Journal of Psychopharmacology
  47. Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients
    Pei Shang, Ada Man‐Choi Ho, Maximilian Tufvesson‐Alm, Daniel R. Lindberg, Caroline W. Grant, Funda Orhan, Feride Eren, Maria Bhat, Göran Engberg, Lilly Schwieler et al. · 2022 · Translational Psychiatry
  48. Partial Volume Correction using Structural–Functional Synergistic Resolution Recovery: Comparison with Geometric Transfer Matrix Method
    Euitae Kim, Miho Shidahara, Charalampos Tsoumpas, Colm J. McGinnity, Jun Soo Kwon, Oliver David Howes, Federico Turkheimer · 2013 · Journal of Cerebral Blood Flow & Metabolism
  49. Molecular imaging as a guide for the treatment of central nervous system disorders
    Euitae Kim, O. Howes, S. Kapur · 2013 · Dialogues in Clinical Neuroscience
  50. Overlapping Neurobiological Substrates for Early-Life Stress and Resilience to Psychosis
    Pamela DeRosse, Anita D. Barber · 2020 · Biological Psychiatry Cognitive Neuroscience and Neuroimaging
  51. Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits
    Karen Brami‐Cherrier, Andrea Anzalone, M Ramos, Ignasi Forné, Fabio M. Macciardi, Axel Imhof, Emiliana Borrelli · 2014 · Molecular Psychiatry
  52. A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis
    Lani Cupo, Eric Plitman, Elisa Guma, M. Mallar Chakravarty · 2021 · Translational Psychiatry
  53. At-risk mental state for psychosis: identification and current treatment approaches
    Andrew David Thompson, Steven Marwaha, Matthew R. Broome · 2016 · BJPsych Advances
  54. Cross-Cutting Advancements Usher in a New Era for Motor Research in Psychosis
    Vijay Anand Mittal · 2016 · Schizophrenia Bulletin
  55. The prodromal phase of psychosis
    Gemma Modinos, Philip K. McGuire · 2014 · Current Opinion in Neurobiology
  56. The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
    Susan F. Sonnenschein, Anthony A. Grace · 2020 · Neuropsychopharmacology
  57. The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study
    Enrico D’Ambrosio, Tarik Dahoun, Antonio F. Pardiñas, Mattia Veronese, Michael Bloomfield, Sameer Jauhar, Ilaria Bonoldi, Maria Rogdaki, Seán Froudist‐Walsh, James Walters et al. · 2019 · Psychiatry Research Neuroimaging
  58. Dopamine signaling enriched striatal gene set predicts striatal dopamine synthesis and physiological activity in vivo
    Leonardo Sportelli, Daniel Paul Eisenberg, Roberta Passiatore, Enrico D’Ambrosio, Linda Antonella Antonucci, Jasmin S. Bettina, Qiang Chen, Aaron L. Goldman, Michael D. Gregory, Kira Griffiths et al. · 2024 · Nature Communications
  59. The enduring centrality of dopamine in the pathophysiology of schizophrenia: in vivo evidence from the prodrome to the first psychotic episode.
    I. Bonoldi, O. Howes · 2013 · Advances in Pharmacology
  60. Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain
    Jacqueline Borg, Simon Červenka, Ralf Kuja‐Halkola, Granville James Matheson, Erik Gunnar Jönsson, Paul Lichtenstein, Susanne Henningsson, Tetsuya Ichimiya, Henrik Larsson, Per Stenkrona et al. · 2015 · Molecular Psychiatry
  61. The Impact of Psychosis on Sexual Functioning: A Systematic Review
    Sebastián Vargas-Cáceres, Nicoletta Cera, Pedro J Nobre, Josep Antoni Ramos‐Quiroga · 2021 · The Journal of Sexual Medicine
  62. Computational models of the “active self” and its disturbances in schizophrenia
    Tim Julian Möller, Yasmin Kim Georgie, Guido Schillaci, Martin Voss, Verena V. Hafner, Laura Kaltwasser · 2021 · Consciousness and Cognition
  63. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [ 18 F]-FDOPA imaging in schizophrenia
    Ilinca Angelescu, Stephen John Kaar, Tiago Reis Marques, Faith Borgan, Mattia Veronesse, Alice Sharman, Anil Sajjala, J.F.W. Deakin, John B. Hutchison, Charles H. Large et al. · 2022 · Journal of Psychopharmacology
  64. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study
    Ragy R. Girgis, Mark Slifstein, Gary Brucato, Lawrence S. Kegeles, Tiziano Colibazzi, Jeffrey Alan Lieberman, Anissa Abi‐Dargham · 2020 · Molecular Psychiatry
  65. Antipsychotics and the Dopamine–Serotonin Connection
    B. Ellenbroek, A. Cesura · 2014 · Topics in medicinal chemistry
  66. Elevated striatal dopamine function in immigrants and their children: a risk mechanism for psychosis
    Romina Mizrahi · 2016 · Intrinsic Activity
  67. Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide
    Abdulla A.‐B. Badawy · 2013 · Psychopharmacology
  68. Leveraging Basic Science for the Clinic—From Bench to Bedside
    Philip Robert Corlett, Geoffrey M. Schoenbaum · 2020 · JAMA Psychiatry
  69. Altered central vision and amacrine cells dysfunction as marker of hypodopaminergic activity in treated patients with schizophrenia
    Florent Bernardin, Thomas Schwitzer, Raymund Schwan, Karine Angioï-Duprez, Fabienne Ligier, Stéphanie Bourion-Bédès, Claire Jansen, Anne Giersch, Vincent Laprévote · 2021 · Schizophrenia Research
  70. Aberrant hippocampus and amygdala morphology associated with cognitive deficits in schizophrenia
    Bradley S. Peterson, Tejal Kaur, Siddhant Sawardekar, Tiziano Colibazzi, Xuejun Hao, Bruce E. Wexler, Ravi Bansal · 2023 · Frontiers in Cellular Neuroscience
  71. D2/D3 dopamine supports the precision of mental state inferences and self-relevance of joint social outcomes
    Joseph M Barnby, Vaughan Bell, Quinton Deeley, Mitul Ashok Mehta, Michael Moutoussis · 2024 · Nature Mental Health
  72. Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings
    Carmen F.M. van Hooijdonk, Marjan Drukker, Elsmarieke van de Giessen, Jan Booij, Jean‐Paul Selten, Thérèse van Amelsvoort · 2022 · Progress in Neurobiology
  73. Early Life Stress Alters Expression of Glucocorticoid Stress Response Genes and Trophic Factor Transcripts in the Rodent Basal Ganglia
    Cynthia Haidee Tran, Cynthia Shannon Weickert, Thomas Wesley Weickert, Duncan Sinclair · 2022 · International Journal of Molecular Sciences
  74. A polygenic score indexing a DRD2-related co-expression network is associated with striatal dopamine function
    Enrico D’Ambrosio, Giulio Pergola, Antonio F. Pardiñas, Tarik Dahoun, Mattia Veronese, Leonardo Sportelli, Paolo Taurisano, Kira Griffiths, Sameer Jauhar, Maria Rogdaki et al. · 2022 · Scientific Reports
  75. Imaging as tool to investigate psychoses and antipsychotics.
    J. Booij, T. van Amelsvoort · 2012 · Handbook of Experimental Pharmacology
  76. Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for Psychosis
    Samuel Knight, Leyla Abbasova, Yashar Zeighami, Justine Y. Hansen, Daniel Martins, Fernando O. Zelaya, Ottavia Dipasquale, Thomas T. Liu, David D. Shin, Matthijs Geert Bossong et al. · 2025 · Biological Psychiatry
  77. Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials
    Naren P Rao, Gary J. Remington · 2013 · Expert Opinion on Investigational Drugs
  78. Abnormal functional connectivity of the striatum in first‐episode drug‐naive early‐onset Schizophrenia
    Yan Zhang, Yue Peng, Yichen Song, Youqi Zhou, Sen Zhang, Ge Yang, Yongfeng Yang, Wenqiang Li, Weihua Yue, Luxian Lv et al. · 2022 · Brain and Behavior
  79. Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human brain
    Yasuharu Yamamoto, Keisuke Takahata, Manabu Kubota, Harumasa Takano, Hiroyoshi Takeuchi, Yasuyuki Kimura, Yasunori Sano, Shin Kurose, Hiroshi Ito, Masaru Mimura et al. · 2020 · NeuroImage
  80. Potassium channel modulators and schizophrenia: an overview of investigational drugs
    Meghan A. Musselman, Eric Huynh, Rachana Kelshikar, Eric Lee, Mohammed Malik, Justin Faden · 2023 · Expert Opinion on Investigational Drugs
  81. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study
    Tarik Dahoun, Antonio F. Pardiñas, Mattia Veronese, Michael Bloomfield, Sameer Jauhar, Ilaria Bonoldi, Seán Froudist‐Walsh, Chiara Nosarti, Carsten Korth, William Hennah et al. · 2018 · Human Molecular Genetics
  82. Stem Cells for Improving the Treatment of Neurodevelopmental Disorders
    Jennifer J. Donegan, Daniel J. Lodge · 2020 · Stem Cells and Development
  83. The Antipsychotic Effects of Omega-3 Fatty Acids in Rats
    Mehmet Hanifi Kokaçya, Ümit Sertan Çöpoğlu, Recep Dokuyucu, Sema İnanır, Oytun Erbaş · 2015 · The American Journal of the Medical Sciences
  84. Regional neural functional efficiency across schizophrenia, bipolar disorder, and major depressive disorder: a transdiagnostic resting-state fMRI study
    Jun Yang, Zhening Liu, Yunzhi Pan, Zebin Fan, Yixin Cheng, Feiwen Wang, Fuping Sun, Guowei Wu, Xuan Ouyang, Haojuan Tao et al. · 2024 · Psychological Medicine
  85. Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging
    Alessio Giacomel, Daniel Martins, Giovanna Nordio, Rubaida Easmin, Oliver David Howes, Pierluigi Selvaggi, Steven Williams, Federico Turkheimer, Marius de Groot, Ottavia Dipasquale et al. · 2025 · Molecular Psychiatry
  86. Ethical Implications for Clinical Practice and Future Research in “At Risk” Individuals
    Fiza Singh, Heline Mirzakhanian, Paolo Fusar‐Poli, Camilo de la Fuente‐Sandoval, Kristin S. Cadenhead · 2012 · Current Pharmaceutical Design
  87. Gradients of striatal function in antipsychotic-free first-episode psychosis and schizotypy
    Marianne Oldehinkel, Jeggan Tiego, Kristina Sabaroedin, Sidhant Chopra, Shona M. Francey, Brian N. O'Donoghue, Vanessa Cropley, Barnaby Nelson, Jessica R. Graham, Lara Baldwin et al. · 2023 · Translational Psychiatry
  88. A Review of Potential Neuroimaging Biomarkers of Schizophrenia-Risk
    Daniel T. Mamah · 2023 · Journal of Psychiatry and Brain Science
  89. The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions
    Brandon Abbs, Rashmin M. Achalia, Adegoke O. Adelufosi, Ahmet Yiğit Aktener, Natalie Jane Beveridge, Savita G. Bhakta, Rachael K. Blackman, Emre Bora, M.S. Byun, Maurice Cabanis et al. · 2012 · Schizophrenia Research
  90. Is neuroimaging clinically useful in subjects at high risk for psychosis?
    Stefan Borgwardt, André Schmidt · 2016 · World Psychiatry
  91. Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management
    Adejoke Y. Onaolapo, Olakunle J. Onaolapo · 2018 · Advances in Pharmacology and Pharmacy
  92. Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis
    Claudia Vingerhoets, Oswald Bloemen, Erik Boot, Geor Bakker, Mariken Beatrijs de Koning, Fabiana da Silva Alves, Jan Booij, Thérèse van Amelsvoort · 2017 · Psychiatry Research Neuroimaging
  93. Animal Models of Relevance to the Schizophrenia Prodrome
    Alice E. Petty, Oliver David Howes, Darryl Walter Eyles · 2021 · Biological Psychiatry Global Open Science
  94. An overview of functional, structural and neurochemical imaging studies in individuals with a clinical high risk for psychosis
    Alice Egerton, Stefan Borgwardt, Stefania Tognin, Oliver David Howes, Philip K. McGuire, Paul Allen · 2011 · Neuropsychiatry
  95. Dopamine dysfunction in schizophrenia
    A. Abi-Dargham · 2014 · Schizophrenia Research
  96. The trace amine-associated receptor 1 regulates presynaptic dopamine function: evidence from preclinical studies and a phase 1b trial in patients with schizophrenia.
    O. Howes, L. Vano, A. Petty, G. Rutigliano, M. Veronese, S. Kaar, G. Nordio, Emanuel F. Lopes, Stephanie J. Cragg, S. Natesan et al. · 2025 · Biological Psychiatry
  97. Illness Phase as a Key Assessment and Intervention Window for Psychosis
    Christian G. Kohler, Daniel H. Wolf, Anissa Abi‐Dargham, Alan Anticevic, Youngsun Cho, Clara Fonteneau, Roberto B. Gil, Ragy R. Girgis, David L. Gray, Jack Grinband et al. · 2022 · Biological Psychiatry Global Open Science
  98. Sexual dysfunctions in drug-naive male patients with first-episode schizophrenia
    Walaa Sabry, Mohamed El Sayed El Taweel, Fadia Zyada · 2017 · Middle East Current Psychiatry
  99. The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study
    Lukasz Smigielski, Diana Wotruba, Valérie Treyer, Julian Rössler, Sergi Papiol, Peter Falkai, Edna Grünblatt, Susanne Walitza, Wulf Rössler A · 2021 · Schizophrenia Bulletin
  100. Is clinical intervention in the ultra high risk phase effective?
    Philip K. McGuire, Sudhakar Selvaraj, Oliver David Howes · 2011 · Brazilian Journal of Psychiatry